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Results: Seventy-one consecutive patients were prospectively 
included in the study. Baseline patient, tumour and 
treatment characteristics are presented in Table 1. 
Preliminary analysis of the first 34 patients with baseline 
SPECT/CT scans showed no association with radiation 
pneumonitis for conventional MLD, whereas there was an 
association with symptomatic radiation pneumonitis for MLD 
to FL 40%. MLDf was larger than MLDc in 13 out of 34 patients 
with a difference of around 5 Gy. All 13 patients developed 
symptomatic RP. Analysis of functional DVH parameters for 
the whole patient cohort is underway. 
 
 
 
Conclusions: Our preliminary analysis shows that SPECT-
determined functional MLD is more associated with the risk of 
symptomatic radiation pneumonitis than total 
MLD.Therefore, functional dosimetric parameters from SPECT 
may be useful in future studies to guide radiotherapy 
treatment planning, in order to reduce the risk of radiation-
induced pulmonary symptoms 
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Purpose/Objective: Intensity Modulated Radiotherapy (IMRT) 
allows dose to be sculpted around target volumes, 
maintaining dose to the tumour whilst reducing dose to 
normal tissues. However, uptake of IMRT for lung cancer 
remains low, as a result of the paucity of clinical data and 
concerns about the impact of the low dose bath on toxicity. 
The Christie has treated 650 lung cancer patients with IMRT 
since 2008. Here we report the results of 106 patients, 
focusing on toxicity. Survival will be reported at a later date. 
Materials and Methods: A retrospective review of the first 
106 patients receiving 6MV inversely planned (6-8 field) Step 
and Shoot IMRT for lung cancer from 2008-2012 was carried 
out. A database was interrogated to correlate planning 
parameters with toxicity.  
Results: 106 patients with a median age of 67 (36-85) were 
included. Patients received a dose of 50-68 Gy in 20-33 
fractions. Seventy three (69%) had non-small cell lung cancer, 
23 (22%) small cell lung cancer, 3 (3%) mixed histology and 6 
(6%) no histology. At presentation, 2 (2%), 17 (16%), 82 (77%) 
and 4 patients (4%) had stage I, II, III and IV disease. 
Treatment modalities were split evenly between concurrent 
(36%), sequential (33%) chemo-radiotherapy and radiotherapy 
alone (31%).  
Mean PTV volume was 586 cc (113.7-1297.2). Mean lung V20, 
V10 and V5 were 27.9% (7.9-35.3), 50.9% (13.4-83.1) and 
64.8% (17.9-98.9). Fifty-two patients (49%) had V5 values > 
65%. Mean dose to the oesophagus was 2462 cGy (482-5102); 
oesophageal V55 and V35 were 4.2% (0-70.8) and 37.6% (0-
79.8). Heart V30 and V5 were 23.5% (0-60.6) and 57.6% (1.7-
100). 
Acute G3 pneumonitis and oesophagitis were observed in 4 
(3.8%) and 18 (17.1%) patients respectively. Late toxicity was 
not available in all patients. 5/76 (6.8%) developed late G3 
pneumonitis and G3 dyspnoea, late G2 cough was reported in 
7/75 (9.7%). Grade 1 and 2 pulmonary fibrosis occurred in 
35/86 (41%) and 4/86 (5%) patients. Oesophageal stricture 
was evident in 3/83 (4%) and 1 patient developed an 
oesophageal fistula.  
There was no significant correlation between lung V5 and 
acute or late lung toxicity, using >65% as a cut off. Similarly, 
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lung toxicity did not correlate with lung V10. There was also 
no relationship between mean oesophageal dose/V35/V55 
and fistula or oesophageal stricture. Increase in PTV volume 
appeared to be significantly associated with grade of acute 
oesophagitis, but this trend was not observed when late 
oesophagitis or acute/late pneumonitis were examined. 
Conclusions: From our experience, IMRT to the thorax is well 
tolerated, with minimal grade 3 toxicity. Contrary to reports, 
we did not observe a correlation between lung V5 and 
acute/late lung toxicity however this data needs to be 
confirmed with a larger number of patients. Data will be 
updated prior to the ESTRO meeting. 
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Purpose/Objective: Current guidelines do not recommend 
the use of elective nodal irradiation for NSCLC, for several 
reasons. One of these is that PET-CT provides adequate 
mediastinal nodal staging; thus, the involved field 
radiotherapy is all the more justified. We present a 
systematic review that compared the published rates of 
elective nodal failures (ENFs), which were defined as regional 
failures that occur without simultaneous or previous local 
recurrence in patients who did or did not undergo PET-CT for 
staging. 
Materials and Methods: Reports of the occurrence of ENFs 
were considered. Only studies that used involved fields and 
specified the number of ENFs in patients with and without 
PET-CT use were included. A chi-squared test was used for 
the comparison of the risk of ENF in patients who were 
staged with and without PET. 
Results: In total, 65 studies that reported the occurrence of 
ENF after radiotherapy for NSCLC were found. Finally, 48 
studies were included and 2158 patients with and 1485 
patients without PET-CT performed before radiotherapy were 
identified. There were 136 (6.3%) and 98 (6.6%) ENFs in 
patients with and without PET-CT, respectively (p = .74). The 
proportion of patients who were treated with SBRT was 
higher in the group with PET-CT (71%) than it was in the 
group without PET-CT (20%; p < .001). In the group of 
patients who were treated with SBRT without PET-CT, there 
were 19 (6.5%) ENFs compared with 106 (6.9%) ENFs in SBRT 
patients with PET-CT (p = .82). After excluding patients who 
were treated with SBRT, we detected 79 ENFs (6.6%) in 1192 
patients without PET-CT, and 30 (4.9%) ENFs in 617 patients 
with PET-CT performed before radiotherapy (p=.16). 
Conclusions: The failure to reduce ENF by PET-CT was 
demonstrated. These data should be regarded in the context 
of the adequacy of reporting the rate of ENF and of the 
clinical relevance of the reported rates. 
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Purpose/Objective: To evaluate brachial plexus toxicity post 
stereotactic body radiation therapy (SBRT) of apically 
situated lung lesions. 
Materials and Methods: We retrospectively identified 41 
patients with 42 apically located tumors, defined as the 
epicenter located superiorly to the aortic arch, and treated 
with SBRT-technique. Median prescription dose per fraction 
was 15 Gy (6-17) and median number of fractions was 3 (3-
10). Primary aim was to evaluate radiation induced 
neurological symptoms defined as radiation induced brachial 
plexopathy and radiation induced upper extremity pain 
according to CTCAE v4.0. No patients had neurological 
extremity symptoms before the treatment.  
Results: Six patients experienced grade 2 (scored 4 times) 
and 3 (scored 4 times) neurologic toxicity after a median of 
9.4 months (4.0-19.1). Two patients had pain + sensory 
alterations, weakness and paralysis of the hand and/or arm, 
3 patients had pain only and 1 patient had sensory 
alterations, numbness and weakness of the arm. These 
patients had a median PTV volume of 84.0cc (51.3-142.0) and 
the median Dmax and D1cc to the plexus were 324.0 Gy (29.9-
523.7) and 83.2Gy (3.0-294.7) (BED3) respectively. All but one 
of these patients had ≤2mm between the PTV and the plexus. 
The patients without neurological symptoms had a median 
PTV-volume of 35cc (10.4-502.6) and the median Dmax and 
median D1cc to the plexus were 24.4 (0.2-483.2) and 3.8 Gy 
(0.1-264.5) (BED3) respectively. Interestingly, 11 patients 
(median follow-up 20.5 months) had Dmax >100Gy (BED3), but 
did not develop neurological symptoms. Median follow-up for 
the entire cohort was 30.1months (0.3-62.7). 
 
 
